Tags : HAE

Biotech

Shire’s Takhzyro (lanadelumab-flyo) Receives FDA Approval Novel Hereditary Angioedema (HAE)

Shots: Approval is based on four clinical studies including P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study (N=125) for 26 wks, administering Takhzyro 300mg Q2W, Q4W and 150 mg Q4W  HELP results (Takhzyro vs PBO): No attack (44% vs 2%); 87% reduction in monthly attacks; post hoc (77% vs 3%) attack free; attacks requiring acute treatment […]Read More